International Scholarly Research Notices / 2013 / Article / Tab 2

Clinical Study

Fecal Calprotectin and Clinical Disease Activity in Pediatric Ulcerative Colitis

Table 2

Three-month outcome of pediatric patients with mild-to-moderate ulcerative colitis according to the clinical disease activity index PUCAI and fecal calprotectin at baseline. The outcome was determined according to physicians global assessment.

No.Disease activity according to the PUCAI (total score)Calprotectin
µg/g of stool
Outcome within 3 months

1Remission (<10)14Remission
214Remission
316Remission*
430Remission
545Remission
669Remission
769Remission
890Remission
9131Remission
10155Flare (within two months)
11189Flare (when tapering corticoid)
12333Remission*
13345Flare
14372Remission
15411Remission
16441Remission
17521Remission
18532Flare (when tapering corticoid)
19581Remission
20628Remission
21663Flare (within a month)
22796Remission
23902Flare*
241052Remission*
251173Flare*
261233Remission
271976Flare (when tapering corticoid)
282295Flare*
294518Flare (within two weeks)
309625Remission
31Mild-to-moderate disease (10–64)7Remission
3255Remission
3387Remission
34327Flare (when tapering corticoid)
35416Remission
36611Lost from followup
37653Flare
38751Flare
39766Flare
40829Flare (ongoing)
41856Remission
42Mild-to-moderate disease (10–34)1067Flare
431110Remission
441127Remission
451599Flare (when tapering corticoid)
461667Flare (within two weeks)
471911Flare (ongoing)
482604Flare
497287Flare (when tapering corticoid)

 *Sample taken on the day of infliximab administration.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.